Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMJ Case Rep ; 15(9)2022 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-36104036

RESUMO

We report the case of a woman in her 60s with intravascular leiomyomatosis. She suffered from numerous non-specific symptoms including weight loss, anaemia and sudden swelling of the left lower extremity. CT imaging showed the presence of an enlarged left ovary and a thrombus extending from the left ovarian venous plexus intruding into the right atrium of the heart. Cancer antigen 125 was 20 U/mL. Pelvic transvaginal ultrasound examination identified two normal ovaries and a mass adjacent to the left ovary. A second opinion on the CT scan was requested at a oncogynaecological multidisciplinary team meeting, where the radiologist of the team identified an intervascular leiomyomatosis. After further investigation, surgical treatment was planned and completed in collaboration with the departments of cardiothoracic and vascular surgery. The patient recovered fully.


Assuntos
Neoplasias Cardíacas , Leiomiomatose , Doenças Ovarianas , Feminino , Átrios do Coração/diagnóstico por imagem , Neoplasias Cardíacas/cirurgia , Humanos , Leiomiomatose/diagnóstico por imagem , Leiomiomatose/cirurgia , Veia Cava Inferior/cirurgia
2.
Ugeskr Laeger ; 180(20)2018 05 14.
Artigo em Dinamarquês | MEDLINE | ID: mdl-29761782

RESUMO

Vulvar intraepithelial neoplasia (VIN) is a rare but premalig-nant condition. VIN has two aetiological pathways: a human papillomavirus (HPV)-dependent pathway, which is a vulvar high-grade squamous intraepithelial lesion (HSIL), and an HPV-independent pathway, called differentiated VIN (d-VIN), associated with lichen sclerosus. d-VIN is more aggressive than vulvar HSIL. In case of symptoms, a biopsy should be performed. The recurrence risk is high: 25-50% regardless of treatment type. We recommend treatment with imiquimod as first choice to avoid mutilating surgery. Particular attention must be payed to immunosuppressed patients with VIN. HPV-vaccine can be discussed with patients with vulvar HSIL.


Assuntos
Carcinoma in Situ , Neoplasias Vulvares , Antineoplásicos/uso terapêutico , Carcinoma in Situ/classificação , Carcinoma in Situ/tratamento farmacológico , Carcinoma in Situ/patologia , Carcinoma in Situ/virologia , Feminino , Humanos , Imiquimode/uso terapêutico , Hospedeiro Imunocomprometido , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/complicações , Vacinas contra Papillomavirus/uso terapêutico , Lesões Pré-Cancerosas , Neoplasias Vulvares/classificação , Neoplasias Vulvares/tratamento farmacológico , Neoplasias Vulvares/patologia , Neoplasias Vulvares/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...